Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 77
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01659-1 · Cited by 951
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001062 · Cited by 394
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Heart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
Seferovic, P. M., Ponikowski, P., Anker, S. D., Bauersachs, J., Chioncel, O., Cleland, J. G. F., de Boer, R. A., Drexel, H., Ben Gal, T., Hill, L., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1531 · Cited by 611
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Titration of medical therapy for heart failure with reduced ejection fraction
Greene, S. J., Fonarow, G. C., DeVore, A. D., Sharma, P. P., Vaduganathan, M., Albert, N. M., Duffy, C. I., Hill, C. L., McCague, K., Patterson, J. H., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.015 · Cited by 500
Self-citationMullens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C., Lassus, J., Tang, W. H. W., Skouri, H., Verbrugge, F. H., Orso, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1697 · Cited by 411
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Wachter, R., Senni, M., Belohlavek, J., Straburzynska-Migaj, E., Witte, K. K., Kobalava, Z., Fonseca, C., Goncalvesova, E., Cavusoglu, Y., Fernandez, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1498 · Cited by 354
Arendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
Hollenberg, S. M., Warner Stevenson, L., Ahmad, T., Amin, V. J., Bozkurt, B., Butler, J., Davis, L. L., Drazner, M. H., Kirkpatrick, J. N., Peterson, P. N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.001 · Cited by 336
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Desai, A. S., Solomon, S. D., Shah, A. M., Claggett, B. L., Fang, J. C., Izzo, J., McCague, K., Abbas, C. A., Rocha, R., Mitchell, G. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.12843 · Cited by 319
Self-citationWorsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Greene, S. J., Bauersachs, J., Brugts, J. J., Ezekowitz, J. A., Lam, C. S. P., Lund, L. H., Ponikowski, P., Voors, A. A., Zannad, F., Zieroth, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.023 · Cited by 303
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
Heart failure drug treatment: the fantastic four
Bauersachs, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1012 · Cited by 290
Rosano, G. M. C., Moura, B., Metra, M., Böhm, M., Bauersachs, J., Ben Gal, T., Adamopoulos, S., Abdelhamid, M., Bistola, V., Čelutkienė, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2206 · Cited by 269
Tomasoni, D., Adamo, M., Lombardi, C. M., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 258
Diabetes, heart failure, and renal dysfunction: The vicious circles
Braunwald, E. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.003 · Cited by 254
Wang, Y., Zhou, R., Lu, C., Chen, Q., Xu, T., & Li, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012272 · Cited by 243
ACC/AHA Versus ESC Guidelines on Heart Failure
van der Meer, P., Gaggin, H. K., & Dec, G. W. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.478 · Cited by 230
Beldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Van Spall, H. G. C., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 216
Schulze, P. C., Bogoviku, J., Westphal, J., Aftanski, P., Haertel, F., Grund, S., von Haehling, S., Schumacher, U., Möbius-Winkler, S., & Busch, M. (2022) · Circulation · doi:10.1161/circulationaha.122.059038 · Cited by 224
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications
Kuwahara, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107863 · Cited by 207
Metra, M., Tomasoni, D., Adamo, M., Bayes-Genis, A., Filippatos, G., Abdelhamid, M., Adamopoulos, S., Anker, S. D., Antohi, L., Böhm, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2874 · Cited by 208
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan
Myhre, P. L., Vaduganathan, M., Claggett, B., Packer, M., Desai, A. S., Rouleau, J. L., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.018 · Cited by 203
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Abnormalities of Potassium in Heart Failure
Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 190
Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., et al. (2023) · JAMA · doi:10.1001/jama.2022.23924 · Cited by 189
Self-citationMeijers, W. C., Bayes‐Genis, A., Mebazaa, A., Bauersachs, J., Cleland, J. G. F., Coats, A. J. S., Januzzi, J. L., Maisel, A. S., McDonald, K., Mueller, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2346 · Cited by 186
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Mentz, R. J., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sarwat, S., Sharma, K., Starling, R. C., Velazquez, E. J., Williamson, K. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.019 · Cited by 178
Self-citationRemote Monitoring for Heart Failure Management at Home
Stevenson, L. W., Ross, H. J., Rathman, L. D., & Boehmer, J. P. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.010 · Cited by 175
Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.4567 · Cited by 178
Self-citationMedical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 176
Tsutsui, H., Albert, N. M., Coats, A. J. S., Anker, S. D., Bayes-Genis, A., Butler, J., Chioncel, O., Defilippi, C. R., Drazner, M. H., Felker, G. M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2848 · Cited by 169
Morrow, D. A., Velazquez, E. J., DeVore, A. D., Desai, A. S., Duffy, C. I., Ambrosy, A. P., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019) · Circulation · doi:10.1161/circulationaha.118.039331 · Cited by 170
Self-citationJCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Docherty, K. F., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.06.020 · Cited by 157
Frailty and heart failure: State‐of‐the‐art review
Talha, K. M., Pandey, A., Fudim, M., Butler, J., Anker, S. D., & Khan, M. S. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13306 · Cited by 181
Vaduganathan, M., Claggett, B. L., Desai, A. S., Anker, S. D., Perrone, S. V., Janssens, S. P., Miličić, D., Arango, J. L., Packer, M., Shi, V. C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.003 · Cited by 148
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction
Teerlink, J. R., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Legg, J. C., Büchele, G. L., Varin, C., Kurtz, C. E., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.12.001 · Cited by 148
Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
Cautela, J., Tartière, J., Solal, A. C., Bellemain-Appaix, A., Théron, A., Tibi, T., Januzzi, J. L., Roubille, F., & Girerd, N. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1835 · Cited by 156
Kozhuharov, N., Goudev, A., Flores, D., Maeder, M. T., Walter, J. E., Shrestha, S., Gualandro, D. M., de Oliveira, M. T., Sabti, Z., Müller, B., et al. (2019) · JAMA · doi:10.1001/jama.2019.18598 · Cited by 153
Frisk, M., Le, C., Shen, X. M., Røe, Å. T., Hou, Y., Manfra, O., da Silva, G. J. J., van Hout, I., Nordén, E. S., Aronsen, J. M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.044 · Cited by 138
‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor
Abdin, A., Anker, S. D., Butler, J., Coats, A. J. S., Kindermann, I., Lainščak, M., Lund, L. H., Metra, M., Müllens, W., Rosano, G. M. C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13646 · Cited by 163
Vaduganathan, M., Mentz, R. J., Claggett, B. L., Miao, Z. M., Kulac, I. J., Ward, J. H., Hernandez, A. F., Morrow, D. A., Starling, R. C., Velazquez, E. J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad344 · Cited by 136
Self-citationGuía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 176
Michos, E. D., Reddy, T. K., Gulati, M., Brewer, L. C., Bond, R. M., Velarde, G., Bailey, A. L., Echols, M. R., Nasser, S. A., Bays, H. E., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100250 · Cited by 131
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 244
Neprilysin Inhibitors in Heart Failure
Bozkurt, B., Nair, A. P., Misra, A., Scott, C. Z., Mahar, J. H., & Fedson, S. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.05.010 · Cited by 134
Read, C., Nyimanu, D., Williams, T., Huggins, D. J., Šulentić, P., Macrae, R. G. C., Yang, P. B., Glen, R. C., Maguire, J. J., & Davenport, A. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017533 · Cited by 133
Device-based therapies for arterial hypertension
Lauder, L., Azizi, M., Kirtane, A. J., Böhm, M., & Mahfoud, F. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0364-1 · Cited by 132
Update on heart failure management and future directions
Choi, H., Park, M., & Youn, J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.428 · Cited by 126
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., Zile, M. R., Anand, I. S., Packer, M., Zannad, F. M., Lam, C. S. P., Janssens, S. P., Jhund, P. S., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.03.002 · Cited by 119
Bakaeen, F. G., Gaudino, M. F. L., Whitman, G. R., Doenst, T., Ruel, M., Taggart, D. P., Stulak, J. M., Benedetto, U., Anyanwu, A., Chikwe, J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.052 · Cited by 131
Self-citationTsutsui, H., Albert, N. M., Coats, A. J. S., Anker, S. D., Bayés‐Genís, A., Butler, J., Chioncel, O. D., deFilippi, C. R., Drazner, M. H., Felker, G. M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.009 · Cited by 130
Kimmoun, A., Takagi, K., Gall, E., Ishihara, S., Hammoum, P., Bèze, N. E., Bourgeois, A., Chassard, G., Pegorer-Sfes, H., Gayat, É., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2103 · Cited by 123
Jering, K., Claggett, B. L., Pfeffer, M. A., Granger, C. B., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2191 · Cited by 114
Sinnenberg, L. E., & Givertz, M. M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.007 · Cited by 136
Metra, M., Adamo, M., Tomasoni, D., Mebazaa, A., Bayés‐Genís, A., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bauersachs, J. K., Belenkov, Y. N., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2888 · Cited by 142
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 112
The therapeutic potential of apelin in kidney disease
Chapman, F. A., Nyimanu, D., Maguire, J. J., Davenport, A. P., Newby, D. E., & Dhaun, N. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00461-z · Cited by 114
Accelerated and personalized therapy for heart failure with reduced ejection fraction
Shen, L., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Petrie, M. C., Desai, A. S., Køber, L., Schou, M., Packer, M., Solomon, S. D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac210 · Cited by 110
Tromp, J., Ponikowski, P. P., Salsali, A., Angermann, C. E., Biegus, J., Blatchford, J., Collins, S. P., Ferreira, J. P., Grauer, C., Kosiborod, M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2137 · Cited by 114
Rao, V. N., Murray, E. M., Butler, J., Cooper, L. B., Cox, Z. L., Fiuzat, M., Green, J. B., Lindenfeld, J., McGuire, D. K., Nassif, M. E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.064 · Cited by 106
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 118
Inciardi, R. M., Bonelli, A., Biering‐Sørensen, T., Cameli, M., Pagnesi, M., Lombardi, C., Solomon, S. D., & Metra, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2562 · Cited by 98
Optimizing Foundational Therapies in Patients With HFrEF
Sharma, A., Verma, S., Bhatt, D. L., Connelly, K. A., Swiggum, E., Vaduganathan, M., Zieroth, S. R., & Butler, J. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.018 · Cited by 107
Butt, J. H., Fosbøl, E. L., Gerds, T. A., Andersson, C., McMurray, J. J. V., Petrie, M. C., Gustafsson, F., Madelaire, C., Kristensen, S. L., Gislason, G., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1800 · Cited by 99
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
DeVore, A. D., Braunwald, E., Morrow, D. A., Duffy, C. I., Ambrosy, A. P., Chakraborty, H., McCague, K., Rocha, R., Velazquez, E. J., & for the PIONEER-HF Investigators (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4665 · Cited by 87
Self-citationCyclic GMP and PKG Signaling in Heart Failure
Numata, G., & Takimoto, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.792798 · Cited by 105
Edema formation in congestive heart failure and the underlying mechanisms
Abassi, Z. A., Khoury, E. E., Karram, T., & Aronson, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.933215 · Cited by 141
Selvaraj, S., Claggett, B. L., Böhm, M., Anker, S. D., Vaduganathan, M., Zannad, F. M., Pieske, B. M., Lam, C. S. P., Anand, I. S., Shi, V. C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.009 · Cited by 91
Piepoli, M. F., Hussain, R. I., Colet, J. C., Dosantos, R., Ferber, P. C., Jaarsma, T., & Edelmann, F. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2076 · Cited by 96
Cannone, V., Cabassi, A., Volpi, R., & Burnett, J. C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133265 · Cited by 85
Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP
Sun, Y., Ma, M., Cao, D., Zheng, A., Zhang, Y., Su, Y., Wang, J., Xu, Y., Zhou, M., Tang, Y., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.320781 · Cited by 89
Spannella, F., Giulietti, F., Filipponi, A., & Sarzani, R. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13002 · Cited by 90
Tsutsui, H., Momomura, S.-I., Saito, Y., Ito, H., Yamamoto, K., Sakata, Y., Desai, A. S., Ohishi, T., Iimori, T., Kitamura, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0854 · Cited by 94
Morrow, D. A., Velazquez, E. J., DeVore, A. D., PRESCOTT, M. F., Duffy, C. I., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz240 · Cited by 89
Self-citationBhatt, A. S., Varshney, A. S., Nekoui, M., Moscone, A., Cunningham, J. W., Jering, K., Patel, P. N., Sinnenberg, L. E., Bernier, T. D., Buckley, L. F., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2163 · Cited by 80
Pascual-Figal, D. A., Bayés‐Genís, A., Beltrán-Troncoso, P., Caravaca-Pérez, P., Martel, A. C., Crespo-Leiro, M. G., Delgado, J. F., Díez, J., Formiga, F., & Manito, N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.754499 · Cited by 83
Rakugi, H., Kario, K., Yamaguchi, M., Sasajima, T., Gotou, H., & Zhang, J. Y. (2022) · Hypertension Research · doi:10.1038/s41440-021-00819-7 · Cited by 87
Contemporary pharmacological treatment and management of heart failure
Bozkurt, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00997-0 · Cited by 93
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.010 · Cited by 81
Hollenberg, S. M., Stevenson, L. W., Ahmad, T., Bozkurt, B., Butler, J., Davis, L. L., Drazner, M. H., Kirkpatrick, J. N., Morris, A. A., Page, R. L., II, et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.002 · Cited by 103
2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.023 · Cited by 86
Acute heart failure: More questions than answers
Tomasoni, D., Lombardi, C., Sbolli, M., Cotter, G., & Metra, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.007 · Cited by 75
Sarno, F., Benincasa, G., List, M., Barabási, A.-L., Baumbach, J., Ciardiello, F., Filetti, S., Glass, K., Loscalzo, J., Marchese, C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01047-z · Cited by 83
Renal protection in chronic heart failure: focus on sacubitril/valsartan
Pontremoli, R., Borghi, C., & Filardi, P. P. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab030 · Cited by 80
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.